Cannapharmarx, INC

CannaPharmaRX, Inc. announced its 2026 growth strategy focusing on European expansion and new cannabis strains, alongside a director's resignation and the revocation of a cease trade order.

CannaPharmaRX, Inc. announced the revocation of its cease trade order but disclosed significant financial challenges including a going concern doubt and substantial debt.

CannaPharmaRX, Inc. has entered into payment schedules with two major debtholders to manage outstanding debts and avoid further defaults, while retaining capital for operations.

CannaPharmaRX announces successful shipments to Israel and Germany, highlighting strong demand and expansion plans.

CannaPharmaRX appoints Constantine Nkafu as interim CEO and adds Constantine Nkafu and Elliot Zemel to its Board of Directors.

CannaPharmaRX, Inc. has engaged Barzily & Co. as its new independent registered public accounting firm, effective November 29, 2024.

CannaPharmaRx reports increased revenue for Q1 2026, yet faces substantial doubt regarding its ability to continue as a going concern due to persistent liquidity challenges and significant liabilities.

CannaPharmaRx reported a Q3 2025 net loss, severe liquidity constraints, defaults under key agreements, and heavy related-party debt amid efforts to expand EU sales and secure financing.

CannaPharmaRx, Inc. reported a significant working capital deficiency and ongoing defaults on lease and royalty payments, raising substantial doubt about its ability to continue as a going concern.

CannaPharmaRx reports increased revenue driven by European sales, but faces substantial doubt about its ability to continue as a going concern due to significant working capital deficiency and accumulated deficit.

CannaPharmaRX reports its first revenue, but also a net loss and ongoing concerns about its ability to continue as a going concern.

CannaPharmaRX reported a net income of $5.36 million for the quarter ended June 30, 2024, primarily driven by changes in the fair value of derivative liabilities, despite ongoing operational losses and a going concern warning.

CannaPharmaRx, a Canadian cannabis cultivator, reported a widened net loss of $11.1 million for 2025 and faces substantial doubt about its ability to continue as a going concern.

CannaPharmaRx's 10-K filing reveals a net loss of $9.9 million for 2024, despite generating $820,137 in revenue for the first time, as the company navigates strategic shifts and operational challenges.

CannaPharmaRX reported a net income of $3.7 million for 2023, a significant turnaround from the previous year's loss, but continues to face substantial doubt about its ability to continue as a going concern.